

Table 22.8
Cancer of the Pancreas (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	1	1	2	1	0	3
1970-1973 ^a	-	-	-	2	2	2	2	0	3
1975-1977 ^b	2.5	2.6	2.2	2.5	2.7	2.3	2.3	2.5	1.9
1978-1980 ^b	2.9	2.7	3.0	2.5	2.6	2.5	5.8	4.5	7.0
1981-1983 ^b	2.7	2.4	3.1	2.5	2.1	3.0	3.6	3.7	3.2
1984-1986 ^b	2.9	2.3	3.5	2.6	2.1	3.1	4.7	3.9	5.3
1987-1989 ^b	3.5	3.3	3.7	3.2	3.0	3.3	5.5	5.1	5.8
1990-1992 ^b	4.3	4.1	4.5	4.4	4.2	4.5	3.6	3.2	4.0
1993-1995 ^b	4.0	3.7	4.3	3.9	3.6	4.2	3.7	3.6	3.7
1996-1998 ^b	4.3	4.6	4.1	4.1	4.6	3.6	3.4	3.1	3.5
1999-2001 ^b	5.1	5.2	5.0	5.0	5.5	4.5	5.6	3.7	7.4
2002-2004 ^b	5.6	5.3	5.9	5.7	5.6	5.8	4.5	3.0	5.7
2005-2009 ^b	7.7	7.8	7.6	7.8	7.8	7.7	6.4	6.8	6.1
2010-2016 ^b	10.5 ^f	10.7 ^f	10.2 ^f	10.4 ^f	10.7 ^f	10.2 ^f	10.3 ^f	10.5 ^f	10.1 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	11.0	11.0	11.0	10.8	10.9	10.7	10.6	9.8	11.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	65,128	33,078	32,050	51,197	26,465	24,732	8,087	3,741	4,346
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	11	10	12	11	10	12	11	9	12
Regional	30	29	30	30	30	30	28	26	29
Distant	52	55	50	52	54	50	56	59	53
Unstaged/Unknown	7	6	8	7	6	8	6	5	7
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	40.6	32.6	48.9	41.3	34.2	49.1	37.7	23.3	49.0
Ages 45-54	17.1	15.2	19.6	16.7	14.6	19.8	16.2	15.5	17.1
Ages 55-64	11.3	10.6	12.3	11.3	10.8	12.1	9.9	8.9	11.2
Ages 65-74	9.1	9.2	9.0	9.1	9.2	9.0	8.0	7.4	8.5
Ages 75+	4.7	5.2	4.4	4.8	5.3	4.4	4.5	2.7	5.1
Ages <65	15.2	13.4	17.6	15.0	13.4	17.3	13.9	11.7	16.4
Ages 65+	6.8	7.4	6.3	6.8	7.4	6.3	6.4	5.8	6.7
Stage ^e :									
All Stages	10.0	10.0	10.0	9.8	9.9	9.8	10.1	9.2	10.8
Localized	39.4	40.9	38.1	39.2	41.2	37.3	36.0	33.5	37.5
Regional	13.3	14.0	12.6	13.2	13.7	12.5	14.5	15.3	13.8
Distant	2.9	2.9	3.0	2.9	2.9	3.0	2.9	2.8	2.9
Unstaged/Unknown	6.1	6.6	5.6	5.4	6.2	4.5	11.1	9.2	12.5

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.⁻ Statistic could not be calculated due to fewer than 25 cases during the time period.